|
Application Number
|
202011031367
|
Application Date
|
2020.09.27
|
|
Publication Number
|
112220919A
|
Publication Date
|
2021.01.15
|
|
Priority Information
|
|
|
International
Classification
|
A61K39/215;A61K39/39;A61K39/385;A61P31/14;C07K14/165;C07K17/14
|
|
|
Applicant(s) Name
|
SHANGHAI NATIONAL ENGINEERING RESEARCH CENTER FOR NANOTECHNOLOGY CO., LTD.
|
|
|
Address
|
|
|
|
Inventor(s) Name
|
CUI DAXIANG;GAO ANG;LIANG HUI;TIAN JING;LI XUELING;SHEN QI
|
|
|
Patent Agency Code
|
31208
|
Patent Agent
|
Dong Mei
|
|
AbstractThe invention belongs to the field of nano materials and biological medicines, and relates to a vaccine, in particular to development of a 2019-nCoV coronavirus nuclear recombinant nano vaccine. The invention also comprises a preparation method of the vaccine and application of the vaccine in animal experiments. The novel coronavirus vaccine contains graphene oxide, carnosine, CpG and novel coronavirus RBD; The carnosine, the CpG and novel coronavirus RBD are combined on a framework of the graphene oxide; the coding sequence of the CpG is as shown in SEQ ID NO 1; and the novel coronavirus RBDrefers to that a novel coronavirus protein receptor binding region can generate a high-titer specific antibody aiming at the RBD in a mouse body, and strong support is provided for prevention and treatment of the novel coronavirus.
|
|